Regeneron Pharmaceuticals Inc (REGN) Stock Price, Trades & News

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	3.24
Equity-to-Asset	0.77
Debt-to-Equity	0.09
Debt-to-EBITDA	0.47
Interest Coverage	80.06
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	6.84	Distress Grey Safe
Beneish M-Score	-2.56	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	7.2
	3-Year EBITDA Growth Rate	5
	3-Year EPS without NRI Growth Rate	-0.5
	3-Year FCF Growth Rate	5
	3-Year Book Growth Rate	12.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	13.04
	Future 3-5Y Total Revenue Growth Rate Estimate	10.02

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	64.74
	9-Day RSI	64.19
	14-Day RSI	59.3
	3-1 Month Momentum %	-19.66
	6-1 Month Momentum %	-24.47
	12-1 Month Momentum %	7.48

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.57
	Quick Ratio	2.96
	Cash Ratio	1.71
	Days Inventory	505.18
	Days Sales Outstanding	138.62
	Days Payable	136.11

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.55
	Dividend Payout Ratio	0.08
	Forward Dividend Yield %	0.57
	5-Year Yield-on-Cost %	0.55
	3-Year Average Share Buyback Ratio	1.2
	Shareholder Yield %	4.93

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	84.55
	Operating Margin %	25.76
	Net Margin %	29.65
	EBITDA Margin %	38.51
	FCF Margin %	25.41
	OCF Margin %	33.6
	ROE %	14.46
	ROA %	11.21
	ROIC %	11.93
	3-Year ROIIC %	-13.62
	ROC (Joel Greenblatt) %	50.5
	ROCE %	14.77
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	8

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	16.19
	Forward PE Ratio	14.41
	PE Ratio without NRI	14.56
	Shiller PE Ratio	17.96
	Price-to-Owner-Earnings	19.13
	PEG Ratio	72.8
	PS Ratio	4.8
	PB Ratio	2.22
	Price-to-Tangible-Book	2.32
	Price-to-Free-Cash-Flow	18.88
	Price-to-Operating-Cash-Flow	14.28
	EV-to-EBIT	12.22
	EV-to-Forward-EBIT	16.74
	EV-to-EBITDA	11.07
	EV-to-Forward-EBITDA	13.69
	EV-to-Revenue	4.26
	EV-to-Forward-Revenue	4.08
	EV-to-FCF	16.78
	Price-to-GF-Value	0.74
	Price-to-Projected-FCF	1.09
	Price-to-Median-PS-Value	0.68
	Price-to-Graham-Number	1.22
	Price-to-Net-Current-Asset-Value	7.96
	Earnings Yield (Greenblatt) %	8.18
	FCF Yield %	5.44
	Forward Rate of Return (Yacktman) %	-0.67

Financials (Next Earnings Date:2026-07-30)

Annual Quarterly TTM

REGN's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NAS:REGN

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Regeneron Pharmaceuticals Inc Executives

Details

GF Value™: $903.5

REGN

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with REGN. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	14,919.6
	EPS (TTM) ($)	41.04
	Beta	0.0298
	3-Year Sharpe Ratio	-0.13
	3-Year Sortino Ratio	-0.18
	Volatility %	32.42
	14-Day RSI	59.3
	14-Day ATR ($)	16.998491
	20-Day SMA ($)	631.6965
	12-1 Month Momentum %	7.48
	52-Week Range ($)	541 - 821.11
	Shares Outstanding (Mil)	104.84

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Regeneron Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Regeneron Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-10-28 08:30	In 109 days
Third quarter earnings results for 2026	2026-10-28	In 108 days
Second quarter earnings conference call for 2026	2026-07-30 08:30	In 19 days
Second quarter earnings results for 2026	2026-07-30	In 18 days
General meeting for 2026	2026-06-12 10:30	611.48 (+1.19%)
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-08 14:00	635.45 (+0.50%)
USD 0.940000 Cash Dividend	2026-05-20	630.30 (-0.03%)
Guidance call for 2026	2026-05-12 13:00	712.77 (-0.31%)
First quarter earnings conference call for 2026	2026-04-29 08:30	731.77 (-2.61%)
First quarter earnings results for 2026	2026-04-29	731.77 (-2.61%)

Show

Entries

Regeneron Pharmaceuticals Inc Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc(REGN)'s stock price today?

The current price of REGN is $664.52. The 52 week high of REGN is $821.11 and 52 week low is $541.00.

When is next earnings date of Regeneron Pharmaceuticals Inc(REGN)?

The next earnings date of Regeneron Pharmaceuticals Inc(REGN) is 2026-07-30.

Does Regeneron Pharmaceuticals Inc(REGN) pay dividends? If so, how much?

The Dividend Yield % of Regeneron Pharmaceuticals Inc(REGN) is 0.55% (As of Today), Highest Dividend Payout Ratio of Regeneron Pharmaceuticals Inc(REGN) was 0.08. The lowest was 0.08. And the median was 0.08. The Forward Dividend Yield % of Regeneron Pharmaceuticals Inc(REGN) is 0.57%. For more information regarding to dividend, please check our Dividend Page.

Guru Commentaries on NAS:REGN

Bronte Capital, Q4 2024 Fund Letter

Bronte Capital, 2024 Q2 Fund Letter

Eddie Yoon, Fidelity Select Health Care Portfolio, Q2 2024 Fund Letter

Franklin Biotechnology Discovery Fund, Q2 2024 Fund Letter

Press Release

	Subject	Date
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	2026-06-11
	REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm	2026-06-10
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	2026-06-04
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	2026-05-28
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	2026-05-21
	REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud	2026-05-20
	Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)	2026-05-18
	TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions	2026-04-02
	Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs	2025-07-07
	REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm	2025-03-10

10/Page

Articles on Regeneron Pharmaceuticals Inc

REGN

8-K - REGENERON PHARMACEUTICALS, INC. (0000872589)

7 days ago

REGN

AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree

Jun 22, 2026

REGN

Regeneron (REGN) Gains Regulatory Milestones for Cemdisiran in gMG Treatment

Jun 22, 2026

REGN

Regeneron Pharmaceuticals (REGN) Announces Key Outcomes from 2026 Annual Shareholders Meeting

Jun 18, 2026

REGN

8-K - REGENERON PHARMACEUTICALS, INC. (0000872589)

Jun 17, 2026

Headlines

Jul 09, 2026

Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis

Seeking Alpha • 6:26am

Jul 08, 2026

White House weighing contenders for FDA's top job

Seeking Alpha • 4:12pm

Jul 06, 2026

Regeneron expects Q2 pre-tax IPR&D charge of ~$127M

Seeking Alpha • 6:28am

Jun 29, 2026

Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing

Seeking Alpha • 4:50pm

Jun 23, 2026

Regeneron myasthenia gravis therapy undergoes U.S. and EU review

Seeking Alpha • 1:34pm

Jun 22, 2026

Apogee soars on AbbVie deal report; analysts bullish

Seeking Alpha • 3:46am

Jun 17, 2026

Ocular to submit Axpaxli NDA for wet AMD in Q4

Seeking Alpha • 8:04am

Jun 15, 2026

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

Benzinga • 3:45pm

Merck, J&J, Bristol decline on proposed CMS drug price rule

Seeking Alpha • 11:32am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.